What question did this study set out to answer?

To evaluate stage-specific ctDNA positivity rates and their impact on clinical decision-making in colorectal cancer patients.

May 29, 2026Journal of Clinical Oncology

Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.

View Full Paper

Ask AI

Bookmark

Authors

EÖEmerik ÖsterlundUniversity of Helsinki GMGiulia MaddalenaThe University of Texas MD Anderson Cancer Center GVGuglielmo VetereUniversity of Pisa

Discussion

Member takes

Implication

Randomized trial assesses ctDNA positivity and clinical actions in colorectal cancer treatment, suggesting improved management based on stage-specific results.

Key Points

To evaluate stage-specific ctDNA positivity rates and their impact on clinical decision-making in colorectal cancer patients.
Patients undergoing curatively intended procedures for stage I-IV CRC were enrolled in the INTERCEPT program.
CtDNA assays were performed postoperatively and every 3 months, categorized into 6-month intervals after treatment completion.
Clinical decisions based on first ctDNA+ results were documented.
28% of patients were ctDNA+ at any time post-definitive therapy, highest in stage IV (48%) and lowest in stage I (3%).
Patients ctDNA- had significantly longer recurrence-free survival (median 62.6 vs 4.8 months, HR 11.6 [95% CI 9.6-14.1]).
Initial management strategies for ctDNA+ patients varied, with 22% screened for MRD trials and 18% experiencing diagnostic escalation.

Cite This Study

Österlund et al. (2026) studied this question.

synapsesocial.com/papers/6a192dbbfab5b468c4416a5e https://doi.org/10.1200/jco.2026.44.16_suppl.3623

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial assesses ctDNA positivity and clinical actions in colorectal cancer treatment, suggesting improved management based on stage-specific results.

Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.

Discussion

Member takes

Implication

Key Points

Cite This Study

Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider